Skip to Main Content

Author Details

Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
2004
51
21
PMIDPaper TitleJournal TitlePublished Year
37502358The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer.Front Med (Lausanne)2023
34780648MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.Blood2022
35632572Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.Vaccines (Basel)2022
36536477Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.Clin Transl Med2022
3649891619S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML).Int J Mol Sci2022
33412552Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells.Acta Haematol2021
35399309Discordant PET Findings and a High Relapse Rate Characterize Hispanics With Hodgkin's Lymphoma Treated With ABVD.Cancer Diagn Progn2021
33712704Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.Oncogene2021
33593728Blood cancer health disparities in the United States Hispanic population.Cold Spring Harb Mol Case Stud2021
33616915Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.Cancer2021
3457203826S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.Cells2021
34680203Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.Cancers (Basel)2021
32409689Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.Leukemia2020
31980730Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.Leukemia2020
30563936Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.Clin Cancer Res2019
31236939Energy metabolism and drug response in myeloid leukaemic stem cells.Br J Haematol2019
28465516Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.Leukemia2017
28432220miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.Blood2017
27028877Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.ChemMedChem2016
26648538Age-related mutations and chronic myelomonocytic leukemia.Leukemia2016
27480386Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.Leukemia2016
27044711A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Leukemia2016
25134459Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.Leukemia2015
26202934β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Leukemia2015
25912019Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.Exp Hematol2015
25721898A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.Leukemia2015
25573989shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Blood2015
25132497BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Cancer Cell2014
27175272STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.Leuk Suppl2014
25316524Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.Genome Biol2014
23100311Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.Blood2013
23887971KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.Cancer Res2013
23904234What challenges remain in chronic myeloid leukemia research?Haematologica2013
23999433PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest2013
23223358BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.Blood2013
22094585Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.Leukemia2012
22825216Pushing the limits of targeted therapy in chronic myeloid leukaemia.Nat Rev Cancer2012
22490804Zebrafish screen identifies novel compound with selective toxicity against leukemia.Blood2012
21867560Advances in the treatment of chronic myeloid leukemia.BMC Med2011
20385359Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.Cancer Cell2010
20799864The new role of microRNAs in cancer.Future Oncol2010
20211135miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.Cell2010
17925491Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.Blood2008
18522544Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.Am J Transplant2008
17475908High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.Blood2007
17717597FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.J Clin Invest2007
16889609Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cells.Am J Transplant2006
16339521Targeting LFA-1 and cd154 suppresses the in vivo activation and development of cytolytic (cd4-Independent) CD8+ T cells.J Immunol2005
16123727CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody.Transplantation2005
15502708Evidence for tissue-directed immune responses: analysis of CD4- and CD8-dependent alloimmunity.Transplantation2004
  • 1 - 50 of 51

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 14
Ashok Kumar Jayavelu
German Cancer Research Center (DKFZ)
Career Start Year 2014
Number of shared co-authors 3
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 10
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 0
Vadym Zaberezhnyy
University of Colorado Anschutz Medical Campus
Career Start Year 2009
Number of shared co-authors 3
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 11
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 3
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 1
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 1
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 0
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 13
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 11
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 1
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 6
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 2
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 5
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 5
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 4
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 2
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 3
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 6
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 0
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 9
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 18
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 3
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 16
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 2
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 17

Collaborators

Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 26
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 20
Anthony D Pomicter
Huntsman Cancer Institute, University of Utah
Co-authored papers 15
Jamshid S Khorashad
Institute of Cancer Research
Co-authored papers 15
Matthew S Zabriskie
University of Utah
Co-authored papers 10
Brian J Druker
Oregon Health & Science University
Co-authored papers 9
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Co-authored papers 8
Dongqing Yan
Inner Mongolia University
Co-authored papers 8
Anna Senina
Huntsman Cancer Institute, The University of Utah
Co-authored papers 7
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Co-authored papers 5
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Jorge Cortes
Georgia Cancer Center
Co-authored papers 5
Hannah M Redwine
Huntsman Cancer Institute, The University of Utah
Co-authored papers 4
Denis-Claude Roy
Universite de Montreal
Co-authored papers 4
Jonathan M Ahmann
Huntsman Cancer Institute, The University of Utah
Co-authored papers 3
Amber D Bowler
Huntsman Cancer Institute, The University of Utah
Co-authored papers 3
Riccardo Baron
Co-authored papers 3
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Katherine E Varley
Huntsman Cancer Institute
Co-authored papers 2
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 2
Thoralf Lange
Hospital Weissenfels
Co-authored papers 2
Richard Moriggl
Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna
Co-authored papers 2
Ravi Bhatia
University of Alabama at Birmingham
Co-authored papers 2
Diana Resetca
University of Toronto
Co-authored papers 2
Hein Than
Singapore General Hospital
Co-authored papers 2
Todd A Fehniger
Washington University School of Medicine
Co-authored papers 1
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 1
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Krzysztof Mr??zek
The Ohio State Comprehensive Cancer Center
Co-authored papers 1
Release 1.2